Download PDF
CC BY 4.0 · J Neuroanaesth Crit Care
DOI: 10.1055/s-0044-1782508
Review Article

A Narrative Review of Neurological Complications of SARS-CoV-2 Vaccination

Parmod K. Bithal 
1   Department of Anesthesiology and Perioperative Medicine, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia
,
Vanitha Rajagopalan 
2   Department of Anaesthesiology, Pain Medicine & Critical Care, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Adverse reactions to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine depict a tropism for neural structures. This narrative review was aimed to discuss published data on the spectrum of neurological side effects of SARS-CoV-2 vaccines, which were accorded emergency use authorization. The majority of the neurological manifestations of SARS-CoV-2 vaccination are usually mild, brief, self-limiting, and easily manageable. Rarely, these side effects can be of serious nature and require hospitalization. High vigilance helps in early identification and treatment of these complications leading to good outcomes. The reported incidence of neurological complications in vaccinated population is a miniscule, and the overall benefits of the vaccine outweigh the risks of side effects. However, it is crucial to conduct larger collaborative multicenter studies to prove or reject the causal association between the SARS-CoV-2 vaccines and the postvaccination neurological side effects. Herein, we have tried to summarize the various neurological manifestations related to SARS-CoV-2 vaccines published in the literature from 2021 to mid-2023.

Keywords

COVID-19 - SARS-CoV-2 vaccine - Postvaccination neurological complications


Publication History

Article published online:
02 May 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 WHO corona virus (COVID-19) dashboard. Accessed July 3, 2023 at: https//covid19.who.int
    PubMedGoogle Scholar
  • 2 Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev 2014; 13 (03) 215-224
    CrossrefPubMedGoogle Scholar
  • 3 Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci 2022; 43 (01) 3-40
    CrossrefPubMedGoogle Scholar
  • 4 Angum F, Khan T, Kaler J, Siddiqui L, Hussain A. The prevalence of autoimmune disorder in women: a narrative review. Cureus 2020; 12 (05) e8094
    PubMedGoogle Scholar
  • 5 Ismail II, Salama S. A systematic review of cases of CNS demyelination following COVID-19 vaccination. J Neuroimmunol 2022; 362 (01) 577765
    CrossrefPubMedGoogle Scholar
  • 6 Al Khames Aga QA, Alkhaffaf WH, Hatem TH. et al. Safety of COVID-19 vaccines. J Med Virol 2021; 93 (12) 6588-6594
    CrossrefPubMedGoogle Scholar
  • 7 Ng JH, Chaudhuri KR, Tan EK. Functional neurological disorders and COVID-19 vaccination. Ann Neurol 2021; 90 (02) 328
    CrossrefPubMedGoogle Scholar
  • 8 Kim DD, Kung CS, Perez DL. Helping the public understand adverse events associated with COVID-19 vaccinations: lessons learnt from functional neurological disorders. JAMA Neurol 2021; 78 (07) 789-790
    CrossrefPubMedGoogle Scholar
  • 9 Göbel CH, Heinze A, Karstedt S. et al. Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. Brain Commun 2021; 3 (03) fcab169
    CrossrefPubMedGoogle Scholar
  • 10 García-Azorín D, Do TP, Gantenbein AR. et al. Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis. J Headache Pain 2021; 22 (01) 108
    CrossrefPubMedGoogle Scholar
  • 11 Finsterer J. Neurological side effects of SARS-CoV-2 vaccinations. Acta Neurol Scand 2022; 145 (01) 5-9
    CrossrefPubMedGoogle Scholar
  • 12 de Gregorio C, Colarusso L, Calcaterra G. et al. Cerebral venous sinus thrombosis following COVID-19 vaccination: analysis of 552 worldwide cases. Vaccines (Basel) 2022; 10 (02) 232-346
    CrossrefPubMedGoogle Scholar
  • 13 Tu TM, Yi SJ, Koh JS. et al. Incidence of cerebral venous sinus thrombosis following SARS-CoV-2 infection vs mRNA SARS-CoV-2 vaccination in Singapore. JAMA Netw Open 2022; 5 (03) e222940
    CrossrefPubMedGoogle Scholar
  • 14 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx 1 n Cov-19 vaccination. N Engl J Med 2021; 384 (22) 2092-2101
    CrossrefPubMedGoogle Scholar
  • 15 Schulz JB, Berlit P, Diener HC. et al; German Society of Neurology SARS-CoV-2 Vaccination Study Group. COVID-19 vaccine associated cerebral venous thrombosis in Germany. Ann Neurol 2021; 90 (04) 627-639
    CrossrefPubMedGoogle Scholar
  • 16 Jaiswal V, Nepal G, Dijamco P. et al. Cerebral venous sinus thrombosis following COVID-19 vaccination: a systematic review. J Prim Care Community Health 2022; 13: 21 501319221074450
    CrossrefPubMedGoogle Scholar
  • 17 Panther EJ, Lucke-Wold B. Subarachnoid hemorrhage: management considerations for COVID-19. Explor Neuroprotective Ther 2022; 2 (02) 65-73
    CrossrefPubMedGoogle Scholar
  • 18 Singh A, Toma F, Uzun G. et al. The interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia. Blood 2022; 139 (23) 3430-3438
    CrossrefPubMedGoogle Scholar
  • 19 Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV.2S vaccination. N Engl J Med 2021; 384 (20) 1964-1965
    CrossrefPubMedGoogle Scholar
  • 20 McGonagle D, De Marco G, Bridgewood C. Mechanism of immunothrombosis in vaccine induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection. J Autoimmun 2021; 121: 102662
    CrossrefPubMedGoogle Scholar
  • 21 Nevzorova TA, Mordakhanova ER, Daminova AG. et al. Platelet factor 4-containing immune complexes induce platelet activation followed by calpain-dependent platelet death. Cell Death Discov 2019; 5: 106
    CrossrefPubMedGoogle Scholar
  • 22 Goldman M, Hermans C. Thrombotic thrombocytopenia associated with COVID-19 infection or vaccination: possible paths to platelet factor 4 autoimmunity. PLoS Med 2021; 18 (05) e1003648
    CrossrefPubMedGoogle Scholar
  • 23 Pang X, Liu H, He X, Ji T, Zhu Y, Cui Y. potential anionic substances binding to platelet factor 4 in vaccine induced thrombotic-thrombocytopenia of ChAdOx 1-S vaccine for SARS-C0V–2. Front Immunol 2022; 12: 782335
    CrossrefPubMedGoogle Scholar
  • 24 Hosseini R, Askari N. A review of neurological side effects of COVID-19 vaccination. Eur J Med Res 2023; 28 (01) 102
    CrossrefPubMedGoogle Scholar
  • 25 Kakovan M, Ghorbani Shirkouhi S, Zarei M, Andalib S. Stroke associated with COVID-19 vaccines. J Stroke Cerebrovasc Dis 2022; 31 (06) 106440
    CrossrefPubMedGoogle Scholar
  • 26 Stefanou MI, Palaiodimou L, Aguiar de Sousa D. et al. Acute arterial ischemic stroke following Covid-19 vaccination: a systematic review and metanalysis. Neurology 2022; 99 (14) e1465-e1474
    CrossrefPubMedGoogle Scholar
  • 27 Rahmig J, Altarsha E, Siepmann T, Barlinn K. Acute ischemic stroke in context of SARS-CoV-2 vaccination: a systemic review. Neuropsychiatr Dis Treat 2022; 18: 1907-1916
    CrossrefPubMedGoogle Scholar
  • 28 Ihle-Hansen H, Bøås H, Tapia G. et al. Stroke after SARS-CoV-2 mRNA vaccine: a nationwide registry study. Stroke 2023; 54 (05) e190-e193
    CrossrefPubMedGoogle Scholar
  • 29 Finsterer J. Neurological adverse reactions to SARS-CoV-2 vaccines. Clin Psychopharmacol Neurosci 2023; 21 (02) 222-239
    CrossrefPubMedGoogle Scholar
  • 30 de Mélo Silva Jr ML, Lopes DP. Large hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case report. Acta Neurol Scand 2021; 144 (06) 717-718
    CrossrefPubMedGoogle Scholar
  • 31 Shimazawa R, Ikeda M. Potential adverse effects in Japanese women who received Tozinameran (BNT162b2 COVID-19 mRNA vaccine. J Pharm Policy Pract 2021; 14: 46
    CrossrefPubMedGoogle Scholar
  • 32 Finsterer J, Korn M. Aphasia seven days after second dose of an mRNA-based SARS-CoV-2 vaccine. Brain Hemorrhages 2021; 2 (04) 165-167
    CrossrefPubMedGoogle Scholar
  • 33 Chida K, Takahashi T, Igarashi S. et al. Rupture of vertebral artery dissecting aneurysm after mRNA anti COVID-19 vaccination. A report of two cases. NMC Case Rep J 2022; 9: 95-100
    CrossrefPubMedGoogle Scholar
  • 34 López-Mena D, García-Grimshaw M, Saldivar-Dávila S. et al. Stroke among SARS-CoV-2 vaccine recipients in Mexico: a nationwide descriptive study. Neurology 2022; 98 (19) e1933-e1941
    CrossrefPubMedGoogle Scholar
  • 35 Lee EJ, Cines DB, Gernsheimer T. et al. Thrombocytopenia following Pfizer and Moderna SARS-COV-2 vaccine. Am J Hematol 2021; 96 (05) 534-537
    CrossrefPubMedGoogle Scholar
  • 36 McMahon DE, Amerson E, Rosenbach M. et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol 2021; 85 (01) 46-55
    CrossrefPubMedGoogle Scholar
  • 37 Purkayastha P, Mckechnie C, Kalkur P, Scully M. Rare case of COVID-19 vaccine-associated intracranial haemorrhage with venous sinus thrombosis. BMJ Case Rep 2021; 14 (09) e245092
    CrossrefPubMedGoogle Scholar
  • 38 Oshida S, Akamatsu Y, Matsumoto Y. et al. Intracranial aneurysm rupture within three days after receiving mRNA anti-COVID-19 vaccination: three case reports. Surg Neurol Int 2022; 13 (117) 117
    CrossrefPubMedGoogle Scholar
  • 39 Syed K, Chaudhary H, Donato A. Central venous sinus thrombosis with subarachnoid hemorrhage following an mRNA COVID-19 vaccine. Are these reports merely coincidental. Am J Case Rep 2021; 22: e933397 , e933397–e5
    CrossrefPubMedGoogle Scholar
  • 40 Frösen J, Piippo A, Paetau A. et al. Remodeling of saccular cerebral artery aneurysm wall is associated with rupture: histological analysis of 24 unruptured and 42 ruptured cases. Stroke 2004; 35 (10) 2287-2293
    CrossrefPubMedGoogle Scholar
  • 41 Finsterer J, Scorza CA, Scorza FA. Guillain-Barre syndrome related to SARS-CoV-2 vaccinations. Clinics (São Paulo) 2022; 77: 100113
    CrossrefPubMedGoogle Scholar
  • 42 Abara WE, Gee J, Marquez P. et al. Reports of Guillain Barre syndrome after COVID-19 vaccination in the United States. JAMA Netw Open 2023; 6 (02) e2253845
    CrossrefPubMedGoogle Scholar
  • 43 Finsterer J. Exacerbating Guillain Barre syndrome eight days after vector based COVID-19 vaccination. Case Rep Infect Dis 2021; 2021: 3619131
    PubMedGoogle Scholar
  • 44 Yu M, Nie S, Qiao Y, Ma Y. Guillain Barres syndrome following COVID-19 vaccines. Front Immunol 2023; 14: 1078197
    CrossrefPubMedGoogle Scholar
  • 45 Nelson KE. Invited commentary: influenza vaccine and Guillain-Barre syndrome—is there a risk?. Am J Epidemiol 2012; 175 (11) 1129-1132
    CrossrefPubMedGoogle Scholar
  • 46 Woo EJ, Mba-Jonas A, Dimova RB, Alimchandani M, Zinderman CE, Nair N. Association of receipt of the Ad 26. COV 2.S COVID 19 vaccine with presumptive Guillain Barre syndrome, February -July 2021. JAMA 2021; 326 (16) 1606-1613
    CrossrefPubMedGoogle Scholar
  • 47 Thant HL, Morgan R, Paese MM, Persaud T, Diaz J, Hurtado L. Guillain Barre syndrome after Ad26. COV-19.S vaccination. Am J Case Rep 2022; 23: e935275-e935271
    CrossrefPubMedGoogle Scholar
  • 48 Rzymski P. Guillain-Barré syndrome and COVID-19 vaccines: focus on adenoviral vectors. Front Immunol 2023; 14: 1183258
    CrossrefPubMedGoogle Scholar
  • 49 Rafati A, Pasebani Y, Jameie M. et al. Association of SARS CoV-2 vaccination or infection with Bell's palsy. A systematic review and metanalysis. JAMA Otolaryngol Head Neck Surg 2023; 149 (06) 493-504
    CrossrefPubMedGoogle Scholar
  • 50 Ish S, Ish P. Facial nerve palsy after COVID-19 vaccination: a rare association or a coincidence. Indian J Ophthalmol 2021; 69 (09) 2550-2552
    CrossrefPubMedGoogle Scholar
  • 51 Albakri K, Khaity A, Atwan H. et al. Bell's palsy and COVID-19 vaccines: a systematic review and meta-analysis. Vaccines (Basel) 2023; 11 (02) 236
    CrossrefPubMedGoogle Scholar
  • 52 Ozonoff A, Nanishi E, Levy O. Bell's palsy and SARS-CoV-2 vaccines. Lancet Infect Dis 2021; 21 (04) 450-452
    CrossrefPubMedGoogle Scholar
  • 53 Hampton LM, Aggarwal R, Ewans SJW, Law B. General determination of COVID 19 vaccines and possible adverse effects. Vaccine 2021; 39: 1478-1480
    CrossrefPubMedGoogle Scholar
  • 54 Woo CJ, Chou OHI, Cheung BMY. Ramsay Hunt syndrome following COVID-19 vaccination. Postgrad Med J 2022; 98 (1164) 738-739
    CrossrefPubMedGoogle Scholar
  • 55 Wan EYE, Chui CSL, Ng VWS. et al. mRNA (BNT162b2) COVID-19 vaccination increased the risk of Bell's palsy: a nested case controlled and self—controlled case series studies. Clin Infect Dis 2022; 76: e291-e298
    PubMedGoogle Scholar
  • 56 Waheed W, Carey ME, Tandan SR, Tandan R. Post COVID-19 vaccine small fiber neuropathy. Muscle Nerve 2021; 64 (01) E1-E2
    CrossrefPubMedGoogle Scholar
  • 57 Sukockienė E, Breville G, Fayolle D, Nencha U, Uginet M, Hübers A. Case series of acute peripheral neuropathies in individuals who received COVID-19 vaccination. Medicina (Kaunas) 2023; 59 (03) 501
    CrossrefPubMedGoogle Scholar
  • 58 Schelke MW, Barcavage S, Lampshire E, Brannagan III TH. Post-COVID-19 vaccine small-fiber neuropathy and tinnitus treated with plasma exchange. Muscle Nerve 2022; 66 (04) E21-E23
    CrossrefPubMedGoogle Scholar
  • 59 Safavi F, Gustafvson L, Walitt B. et al. Neuropathic symptoms with SARS-CoV-2 vaccination. MedRxiv 2022; (e-pub ahead of print). DOI: 10.1101/2022.05.16.22274439.
    CrossrefPubMedGoogle Scholar
  • 60 Schwartz B, Moudgil S, Pollina F, Bhargava A. Small fiber neuropathy after SARS-CoV-2 vaccination. and infection: a case-based comparison. Cureus 2023; 15 (08) e43600
    PubMedGoogle Scholar
  • 61 Queler SC, Towbin AJ, Milani C, Whang J, Sneag DB. Parsonage Turner syndrome following COVID-19 vaccination: MR neurography. Radiology 2022; 302 (01) 84-87
    CrossrefPubMedGoogle Scholar
  • 62 van Alfen N. Clinical and pathophysiological concepts of neuralgic amyotrophy. Nat Rev Neurol 2011; 7 (06) 315-322
    CrossrefPubMedGoogle Scholar
  • 63 Wan EYF, Chui CSL, Wang Y. et al. Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: a self-controlled case series and nested case-control study. Lancet Reg Health West Pac 2022; 21: 100393
    PubMedGoogle Scholar
  • 64 Florea A, Wu J, Qian L. et al. Risk of herpes zoster following mRNA COVID-19 vaccine administration. Expert Rev Vaccines 2023; 22 (01) 643-649
    CrossrefPubMedGoogle Scholar
  • 65 Shahrudin MS, Mohamed-Yassin MS, Nik Mohd Nasir NM. Herpes zoster following COVID-19 vaccine booster. Am J Case Rep 2023; 24: e938667
    PubMedGoogle Scholar
  • 66 Walsh EE, Frenck Jr RW, Falsey AR. et al. Safety and immunogenicity of two mRNA based COVID-19 vaccine candidates. N Engl J Med 2020; 383 (25) 2439-2450
    CrossrefPubMedGoogle Scholar
  • 67 Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines: a new era in vaccinology. Nat Rev Drug Discov 2018; 17 (04) 261-279
    CrossrefPubMedGoogle Scholar
  • 68 Furer V, Zisman D, Kibari A. et al. Herpes zoster following BNT162b2 mRNA COVID-19 vaccine in patients with autoimmune inflammatory rheumatic disease. Rheumatology (Oxford) 2021; 60 (Si): Si 90-95
    CrossrefPubMedGoogle Scholar
  • 69 Kaulen LD, Doubrovinskaia S, Mooshage C. et al. Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series. Eur J Neurol 2022; 29 (02) 555-563
    CrossrefPubMedGoogle Scholar
  • 70 Nabizadeh F, Noori M, Rahmani S, Hosseini H. Acute dissemination encephalomyelitis (ADEM) following COVID 19 vaccine: a systematic analysis. J Clin Neurosci 2023; 111: 57-70
    CrossrefPubMedGoogle Scholar
  • 71 Rinaldi V, Bellucci G, Buscarinu MC. et al. CNS inflammatory demyelinating events after COVID-19 vaccines: a case series and systematic review. Front Neurol 2022; 13: 1018785
    CrossrefPubMedGoogle Scholar
  • 72 Ancau M, Liesche-Starnecker F, Niederschweiberer J. et al. Case series: acute hemorrhagic encephalomyelitis after SARS-CoV-2 vaccination. Front Neurol 2022; 12: 820049
    CrossrefPubMedGoogle Scholar
  • 73 Abdelhady M, Husain MA, Hawas Y. et al. Encephalitis following COVID−19 vaccination: a systematic analysis. Vaccines (Basel) 2023; 11 (03) 576
    CrossrefPubMedGoogle Scholar
  • 74 Huang YF, Ho TC, Chang CC. et al. Rare adverse effect of COVID−19 vaccine on autoimmune encephalitis. Vaccines (Basel) 2022; 10 (07) 1114
    CrossrefPubMedGoogle Scholar
  • 75 Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. The how's and what's of vaccine reactogenicity. NPJ Vaccines 2019; 4: 39
    CrossrefPubMedGoogle Scholar
  • 76 Al-Mashdali AF, Ata YM, Sadik N. Post-COVID-19 vaccine acute hyperactive encephalopathy with dramatic response to methylprednisolone: a case report. Ann Med Surg (Lond) 2021; 69: 102803
    PubMedGoogle Scholar
  • 77 Mirmosayyeb O, Ghaffary EM, Vaheb S, Pourkazemi R, Shaygannejad V. Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccines: a systematic review. Rev Neurol (Paris) 2023; 179 (04) 265-281
    CrossrefPubMedGoogle Scholar
  • 78 Alluqmani M. New onset multiple sclerosis post COVID-19 vaccination and correlation with possible predictors in case-controlled study. Cureus 2023; 15 (03) e36323
    PubMedGoogle Scholar
  • 79 Dias ASO, Sacramento PM, Lopes LM. et al. TLR-2 and TLR-4 agonists favor expansion of CD4+ T cell subsets implicated in the severity of neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 2019; 34: 66-76
    CrossrefPubMedGoogle Scholar
  • 80 Taieb A, Mounira EE. Pilot study of SARS-CoV-2 vaccine induced pituitary diseases: a mini review from diagnosis to pathophysiology. Vaccines (Basel) 2022; 10 (12) 2004
    CrossrefPubMedGoogle Scholar
  • 81 Ishay A, Shacham EC. Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?. BMC Endocr Disord 2023; 23 (01) 47
    CrossrefPubMedGoogle Scholar
  • 82 Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 2021; 20 (04) 102792
    CrossrefPubMedGoogle Scholar
  • 83 Ziogas A, Netea MG. Trained immunity-related vaccines: innate immune memory and heterologous protection against infections. Trends Mol Med 2022; 28 (06) 497-512
    CrossrefPubMedGoogle Scholar
  • 84 Lechien JR, Diallo AO, Dachy B. et al. COVID-19: post vaccine smell and taste disorders: report of 6 cases. Ear Nose Throat J 2024; 103 (02) NP104-NP107
    CrossrefPubMedGoogle Scholar
  • 85 Keir G, Maria NI, Kirsch CFE. Unique imaging findings of neurologic phantosmia following Pfizer-BioNtech COVID-19 vaccination: a case report. Top Magn Reson Imaging 2021; 30 (03) 133-137
    CrossrefPubMedGoogle Scholar